GSTM1 and paroxysmal nocturnal hemoglobinuria: The PADDOCK study (NCT02588833) investigated APL-2 as monotherapy in untreated PNH patients with meaningful intravascular hemolysis (defined as LDH >2 times ULN and Hb <10.5 g/dL) (118).